40
Pharma & HealthcareAvoid
Nippon India Pharma
Nippon India · Direct–Growth · rank #12 of 18 by Smart Score
Data updated
Trailing returns
1 Year
14.1%
+11.1% vs index
3 Years
19.6%
+8.1% vs index
5 Years
13.7%
+3.4% vs index
Since launch
17.7%
Year-by-year performance
2021
+25.1%-5.5% vs index
2022
-9.1%-12.9% vs index
2023
+40.4%+13.8% vs index
2024
+35.3%+19.6% vs index
2025
-2.5%-10.1% vs index
2026
+13.5%+15.6% vs index
Why this score
Nippon India Pharma scores 40/100 — #12 of 18 Pharma & Healthcare fund (Avoid). It stands out for volatility and fund size — beating 91% of peers on volatility. The main drag is its 3y return (better than only 5% of peers).
Each bar shows the fund's percentile vs Pharma & Healthcare peers — a longer bar beats more of the category.
3Y return19.64% · 5th percentile in category
5Y return13.74% · 17th percentile in category
Volatility12.97 · 91st percentile in category
Fund size9279.11 Cr · 97th percentile in category
Sharpe ratio1.02 · 31st percentile in category
1Y return14.10% · 21st percentile in category
Top holdings
1.Sun Pharmaceutical Industries Ltd13.31%
2.Lupin Ltd7.25%
3.Divi's Laboratories Ltd6.52%
4.Cipla Ltd6.03%
5.Apollo Hospitals Enterprise Ltd5.3%
35 disclosed equity positions · portfolio as of Jul 2026 · weights are % of total corpus.